Table 1: Baseline demographics and clinical characteristics.

All PatientsRisk Category at Initial MM Diagnosis
High RiskStandard RiskUnknown Risk
nnnn

All patients, n ()200100.055100.0113100.032100.0

Age (years) at initial MM diagnosis

 Mean (SD)64.59.262.910.664.58.367.19.5

 < 65 years, n (%)10351.53360.05447.81650.0

 ≥ 65 years, n (%)9748.52240.05952.21650.0

Age (years) at RRMM diagnosis

 Mean (SD)66.38.964.410.566.67.968.79.1

 < 65 years, n (%)8542.53156.44539.8928.1

 ≥ 65 years, n (%)11557.52443.66860.22371.9

Sex, n ()

 Male12361.53360.07465.51650.0

 Female7738.52240.03934.51650.0

ISS stage at initial MM diagnosis, n ()

 Stage I2613.047.31412.4825.0

 Stage II8140.51934.65346.9928.1

 Stage III8844.03156.44237.21546.9

 Unknown52.511.843.5

 Impaired renal function, n (%)126.0610.943.526.3

Received stem cell transplant as part of first-line (induction) therapy, n ()

 Autologous SCT6834.01934.64035.4928.1

 Tandem (double) autologous SCT136.511.887.1412.5

 SCT not received11959.53563.66557.51959.4

First-line (induction) systemic treatment regimens, n ()

 Bortezomib + dexamethasone5527.5712.73732.71134.4

 Bortezomib + thalidomide + 
dexamethasone
2713.51323.6119.739.4

 Melphalan + prednisone + 
bortezomib
2613.0814.61412.4412.5

 Melphalan + prednisone +
thalidomide
2412.0610.91210.6618.8

 Vincristine + doxorubicin + 
dexamethasone
189.011.81412.439.4

 Melphalan + prednisone147.059.198.0

 Bortezomib + cyclophosphamide + 
dexamethasone
126.0814.632.713.1

 Other induction regimens with 
frequency of <5 patients
2412.0712.71311.5412.5

Vital status at chart abstraction date, n ()

 Alive10150.52036.47263.7928.1

 Deceased9949.53563.64136.32371.9

Duration (months) of follow-up, from RRMM diagnosis to death/last available medical record, median52385332

SCT = stem cell transplant, SD = standard deviation, and ISS = International Staging System.
High risk: gene rearrangements del(17p), t(4;14), or t(14;16). Standard risk: all patients with known cytogenetics not classified as high risk. Unknown risk: patients with unknown cytogenetics.
Stage I: serum β2-microglobulin < 3.5 mg/L and serum albumin ≥ 3.5 g/dL. Stage II: not stage I or III. Stage III: serum β2-microglobulin ≥ 5.5 mg/L.